Vascular Therapies


Vascular Therapies is a biotechnology company focused on improving patient outcomes by reducing surgical stenosis in patients with kidney and vascular disease. They have developed Sirogen™, an investigational sirolimus formulation for local, perivascular drug delivery, currently undergoing clinical trials to determine its safety and effectiveness in improving vascular access outcomes for hemodialysis patients.

Industries

biotechnology
health-care
pharmaceutical

Nr. of Employees

small (1-50)

Vascular Therapies

Cresskill, New Jersey, United States, North America


Products

Bioresorbable sirolimus-eluting collagen implant for arteriovenous access

An investigational bioresorbable collagen-based implant that delivers sirolimus locally around the arteriovenous anastomosis to reduce intimal hyperplasia and help maintain fistula blood flow for hemodialysis.


Services

Multinational Phase III randomized clinical trial for perivascular drug-eluting implant

Execution of a multicenter randomized clinical study to evaluate safety and effectiveness of a perivascular sirolimus-eluting collagen implant for arteriovenous fistula creation, including endpoint assessment and site coordination.

Scientific presentations and publication support

Preparation and dissemination of clinical and translational data through conference presentations and downloadable scientific materials.

Expertise Areas

  • Vascular access therapeutics
  • Perivascular/local drug delivery
  • Clinical trial management for implantable devices (Phase III RCTs)
  • Translational medicine (bench-to-bedside)
  • Show More (4)

Key Technologies

  • Bioresorbable collagen biomaterials
  • Local sirolimus elution
  • Perivascular drug-eluting implants
  • Randomized controlled trial methodologies (Phase III)
  • Show More (2)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.